Name: MarketsandMarkets ImmunoBio Series USA Edition 2024
Start: 2024-06-20
End: 2024-06-21
Location: Boston, USA

WHAT TO EXPECT

Biomarker Discovery Techniques: Explore novel strategies, including genomics, proteomics, metabolomics, and bioinformatics, to identify cutting-edge biomarkers.
Precision Medicine Tailoring: Understand the pivotal role of biomarkers in customizing treatments for individual patients, enhancing efficacy, and minimizing side effects.
Rigorous Biomarker Validation: Learn strategies and overcome challenges in validating biomarkers for clinical use, ensuring robust and reliable results.
Clinical Applications Across Disorders: Delve into biomarker applications in cancer, immunology, neurodegenerative disorders, and cardiovascular conditions for targeted advancements.
Bioinformatics and AI Analysis: Attend workshops and sessions on biomarker data analysis, employing machine learning and artificial intelligence approaches for comprehensive insights.
Biomarker-Based Diagnostics Development: Gain insights into the development and commercialization of diagnostic tests and platforms based on biomarkers.
Regulatory Frameworks for CDx: Stay updated on current regulatory frameworks for CDx development, facilitating smoother approvals and applications.
Expanding Biomarker Testing Access: Navigate reimbursement landscapes through cross-sector collaborations to widen access to biomarker testing.
Innovative Strategies in CDx Development: Implement new CDx strategies to bring innovative therapies to the clinic, ensuring effective market access in line with global trends.

Collaboration for Advancement: Explore sessions on fostering collaboration among academia, industry, and government agencies to drive biomarker research forward.

Cutting-Edge Insights: Access the latest advancements in biomarker discovery, precision medicine, and clinical applications spanning cancer, immunology, neurodegenerative disorders, and cardiovascular biomarkers.
Innovative Immunotherapy: Dive into immune-oncology projects, exploring antibodies, cellular therapy, and immune checkpoint research. Contribute to interactive discussions, share your work, and stay updated on cutting-edge technologies and platforms.
Networking and Collaboration: Connect with industry leaders, researchers, and peers. Foster collaborations, engage in thought-provoking discussions, and explore partnership opportunities.
Professional Development: Enhance your skills with workshops on biomarker data analysis, machine learning, and artificial intelligence applications. Learn best practices and methodologies for biomarker and IO research.
Practical Applications: Discover how research translates into real-world applications. Explore exhibitor showcases, demonstrations, and case studies, gaining insights into the latest tools and technologies.
Personal and Industry Growth: Step out of your comfort zone, engage in interactive roundtables, and contribute to key discussions. Elevate your personal and professional growth within the dynamic fields of biomarker research and immunotherapy.

Engage in groundbreaking research, expand your network, and drive innovation at the Immunobio Series, where science meets collaboration.

CONFERENCE AGENDA

Registration	08:15 - 08:55
Opening Remarks from the Chairperson	08:55 - 09:00
Keynote Presentation- Regulatory Framework for Biomarker Diagnostics: Insights and Strategies (Reserved Slot for Platinum Sponsor)	09:00 - 09:30
Modeling Strategies for Biomarker-driven Drug Discovery: PK/PD, QSP, and MIDD	09:30 - 10:00
Reserved Slot for Gold Sponsor	10:00 - 10:30
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:30 - 11:15
Reserved Slot for Silver Sponsor	11:15 - 11:45
Advancing Digital Pathology in biomarker identification to revolutionize patient stratification	11:45 - 12:15
Facilitating Agile Global Drug Development with Precision Medicine-Driven Biomarker Deployment: Ensuring Harmonized Assays Across Varied Regional Regulations Zheng Feng, Head, Molecular Biomarkers & Genomics, EMD Serono	12:15 - 12:45
Tumor Immune Microenvironment: A Novel Biomarker to Predict Immunotherapy Outcomes Tyler Nielsen, Sr Scientist, Oncocyte Corporation	12:45 - 13:15
Lunch and Poster Presentation \| One-to-One Networking Meetings	13:15 - 14:15
Biomarkers and Pharmacokinetics of Monoclonal Antibodies Ravinder Singh, Professor of Laboratory Medicine and Pathology, Mayo Clinic	14:15 - 14:45
A Public-Private Consortium for Evaluation of Assays for Non-invasive Tumor Gene Expression Profiling Althea Lang, Scientific Project Manager, Foundation for the National Institutes of Health	14:45 - 15:15
Dissection of the Tumor Microenvironment Using Spatial Transcriptomics and Deep Learning	15:15 - 15:45
Afternoon Refreshments and Poster Presentation \| One-to-One Networking Meetings	15:45 - 16:30
Predictive Modeling in Biomarker Research: Harnessing AI for Prognostic Signatures	16:30 - 17:00
Panel Discussion: Real world data for precision oncology based smart enrollment	17:00 - 17:30
Closing Remarks from the Chairperson	17:30 - 17:30

Registration	08:15 - 08:55
Opening Remarks from the Chairperson	08:55 - 09:00
Keynote Presentation (Reserved for Platinum Sponsor)	09:00 - 09:30
ADC drug and its applications Siamak Tabrizi, Senior Scientist, Immunitas Therapeutics	09:30 - 10:00
Reserved Slot for Gold Sponsor	10:00 - 10:30
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:30 - 11:15
Reserved Slot for Silver Sponsor	11:15 - 11:45
SUPLEXA therapeutic cells, a clinically derisked cell therapy platform with unique mechanisms of action for treating solid cancers Frank Borriello, Founder and CEO, Alloplex Biotherapeutics	11:45 - 12:15
Reserved Slot for Sponsor	12:15 - 12:45
ProtoNKTM Cells from Pluripotent Stem Cells: Therapeutics for All Patients Shi-Jiang (John) Lu, President and CEO, HebeCell Corporation	12:45 - 13:15
Lunch and Poster Presentation \| One-to-One Networking Meetings	13:15 - 14:15
Improving efficacy of CPI’s by selected combination therapy	14:15 - 14:45
Novel mRNA-based Immunotherapy Vaccines	14:45 - 15:15
Oncolytic viruses in the era of Checkpoint Blockade	15:15 - 15:45
Afternoon Refreshments and Poster Presentation \| One-to-One Networking Meetings	15:45 - 16:30
Challenges and Opportunities for the development of ADCs, bispecific immunomodulatory therapies, and combination Rakesh Dixit, CEO, Bionavigen	16:30 - 17:00
Panel Discussions - Innovations in Immunotherapy: Unravelling the Trifecta - Precision Immunology, Cancer Microbiome, and CAR-T Cell Therapy for Personalized Cancer Treatment	17:00 - 17:30
Closing Remarks from the Chairperson	17:00 - 17:00

Registration	08:15 - 08:55
Opening Remarks from the Chairperson	08:55 - 09:00
Keynote Presentation - Challenges and Strategies in CDx Development for Supporting Clinical Trials for Innovative Medicine David Yu, Director, Precision Medicine and Translational Medicine, Bristol Myers Squibb	09:00 - 09:30
From Assay Development to Commercialization: CDx Strategy in Genetics Medicine Melis McHenry, Associate Director, Precision Medicine CDx, Regeneron	09:30 - 10:00
Solution Provider Presentation-Reserved for Gold Sponsor	10:00 - 10:30
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:30 - 11:15
Solution Provider Presentation (Reserved for Silver Sponsor)	11:15 - 11:45
Clinical decision rule guided cut-point selection for companion diagnostic (CDx) development Wenting Wang, Oncology Biomarker Statistics Team Lead, Sanofi	11:45 - 12:15
Exploring International Regulatory and Commercial Considerations to shape the Future of Diagnostics	12:15 - 12:45
Global Commercialization and fast-tracked Market Access Strategies for Companion Diagnostics	12:45 - 13:15
Lunch and Poster Presentation \| One-to-One Networking Meetings	13:15 - 14:15
Th1/Th2 cytokine measurements in culture supernatants after ex vivo stimulation of human PBMCs to assess cellular immune response in vaccine studies Bhaskarjyoti Sarmah, Associate Scientific Director, Clinical Biomarkers, Moderna	14:15 - 14:45
Innovative Safety Biomarker Applications to Drug Development	14:45 - 15:15
Advancements in Imaging Biomarkers for Neurodegenerative Diagnosis and Monitoring	15:15 - 15:45
Afternoon Refreshments and Poster Presentation \| One-to-One Networking Meetings	15:45 - 16:30
Panel Discussion: Opportunities and Challenges in Biomarker Testing: Comparing Oncology and Non-Oncology Perspectives	16:30 - 17:00
Closing Remarks from the Chairperson	17:00 - 17:00

Registration	08:15 - 08:55
Opening Remarks from the Chairperson	08:55 - 09:00
Keynote Presentation (Reserved for Platinum Sponsor)	09:00 - 09:30
Innovative Preclinical Models for Investigating Tumor-Immune Interactions	09:30 - 10:00
Solution Provider Presentation (Reserved for Gold Sponsor)	10:00 - 10:30
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:30 - 11:15
Solution Provider Presentation (Reserved for Silver Sponsor)	11:15 - 11:45
Translational approach in developing right IO therapy	11:45 - 12:15
Development of new generation DNA vaccines	12:15 - 12:45
Combination Strategies to Overcome Resistance to Anti-PD-1/PD-L1 Therapies	12:45 - 13:15
Lunch and Poster Presentation \| One-to-One Networking Meetings	13:15 - 14:15
Future opportunities in clinical development of ICI’s	14:15 - 14:45
The Intersection of Immunology and Oncology: Advancing Targeted Therapy Paradigms	14:45 - 15:15
Challenges and Opportunities in Validating Preclinical Models for Immuno-Oncology Drug Development	15:15 - 15:45
Afternoon Refreshments and Poster Presentation \| One-to-One Networking Meetings	15:45 - 16:30
Panel Discussion: Immunotherapy Frontiers: Integrating Precision Immunology, Cancer Microbiome, and CAR-T Therapies for Tailored Patient Care	16:30 - 17:00
Closing Remarks from the Chairperson	17:00 - 17:00